Loading patent…
AssigneeNanjing Ruiying Runze Biopharmaceutical Technology Co., Inc.
InventorsJing Shang, Dongsheng Yu, Youqing Tian, Huali Wu, Lin Ding, Jun Liu
Estimating the term…
Disclosed is a composition containing active components of Dracocephalum moldavica L. against myocardial ischemia-reperfusion injury (MIRI). The composition consists of active components and a pharmaceutically acceptable carrier, wherein the active components comprise luteolin, kaempferol and luteolin-7-O-glucoside. Pharmacodynamic experiments show that these three components can be combined together to synergistically treat myocardial ischemia-reperfusion injury.
A method for treating myocardial ischemia-reperfusion injury comprising administering a pharmaceutical composition comprising luteolin, kaempferol, luteolin-7-O-glucoside and a pharmaceutically accepted carrier, wherein the molar ratio among luteolin, kaempferol and luteolin-7-O-glucoside is 0.7-2.2:2.1-4.1:0.6-2.4.
A method for treating myocardial ischemia-reperfusion injury comprising administering a pharmaceutical composition consisting of pharmaceutical active component and pharmaceutically accepted carrier, the pharmaceutical active components comprising luteolin, kaempferol, luteolin-7-O-glucoside, wherein the molar ratio among luteolin, kaempferol and luteolin-7-O-glucoside is 1.1-1.6:2.8-3.5:1.0-1.7.
Dependencies are inferred from the claim text.